Multiple Sclerosis Relapsing-remitting
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis Relapsing-remitting.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Teva (dimethyl fumarate) — Teva GmbH
EMA revoked the marketing authorization for Teva's dimethyl fumarate product.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Neuraxpharm (dimethyl fumarate) — Laboratorios Lesvi S.L.
The EMA has revoked the Dimethyl fumarate product from Laboratorios Lesvi S.L. for relapsing-remitting multiple sclerosis.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Polpharma (dimethyl fumarate) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
EMA revoked the Dimethyl fumarate Polpharma product, a therapy for relapsing-remitting multiple sclerosis, indicating withdrawal of authoriz…
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Ireland Limited
EMA revoked the marketing authorization for dimethyl fumarate (Mylan Ireland Limited) intended for multiple sclerosis (relapsing-remitting).
-
EMA withdrawal · 2022-11-03EMA Application withdrawn: Dimherity (dimethyl fumarate) — Sandoz GmbH
The EMA withdrew the application for Dimherity (dimethyl fumarate) by Sandoz GmbH for multiple sclerosis relapsing-remitting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2020-06-17EMA Application withdrawn: Fingolimod Mylan (fingolimod hydrochloride) — Mylan Ireland Limited
The EMA withdrew the application for Fingolimod Mylan (fingolimod hydrochloride) from consideration for relapsing-remitting multiple scleros…